Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
11.61 USD -2.27% Intraday chart for KalVista Pharmaceuticals, Inc. -7.05% -5.22%
12:01am Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing MT
Apr. 22 Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing
MT
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
BU
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
KalVista Pharmaceuticals : Corporate Presentation May 2024
PU
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
BU
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
BU
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors
CI
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
BU
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
BU
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
CI
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat
AQ
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
BU
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALV Stock
  4. News KalVista Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW